Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis

被引：73

作者：

Bouma, BN

Mosnier, LO

机构：

[1] Scripps Res Inst, Dept Mol & Expt Med MEM 180, La Jolla, CA 92037 USA

[2] Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, Utrecht, Netherlands

来源：

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS | 2003年 / 33卷 / 5-6期

关键词：

TAFI; carboxypeptidase; coagulation; fibrinolysis;

D O I：

10.1159/000083832

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The thrombin-catalysed conversion of plasma fibrinogen into fibrin and the development of an insoluble fibrin clot are the final steps of the coagulation cascade during haemostasis. A delicate balance between coagulation and fibrinolysis determines the stability of the fibrin clot. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) plays an important role in this process. TAFI is activated by thrombin and protects the fibrin clot against lysis. The role of TAFI in bleeding and thrombotic disorders is discussed as well as its novel emerging role in wound healing and inflammation. Copyright (C) 2004 S. Karger AG, Basel.

引用

收藏

页码：375 / 381

页数：7

相关论文

共 58 条

[1] FACTOR-XI DEFICIENCY IN ASHKENAZI JEWS IN ISRAEL [J].

ASAKAI, R ;

CHUNG, DW ;

DAVIE, EW ;

SELIGSOHN, U .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :153-158

[2] TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].

Bajzar, L ;

Morser, J ;

Nesheim, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608

[3] PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].

BAJZAR, L ;

MANUEL, R ;

NESHEIM, ME .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484

[4] The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent [J].

Bajzar, L ;

Nesheim, ME ;

Tracy, PB .

BLOOD, 1996, 88 (06) :2093-2100

[5] DENTAL SURGERY IN PATIENTS WITH SEVERE FACTOR-XI DEFICIENCY WITHOUT PLASMA REPLACEMENT [J].

BERLINER, S ;

HOROWITZ, I ;

MARTINOWITZ, U ;

BRENNER, B ;

SELIGSOHN, U .

BLOOD COAGULATION & FIBRINOLYSIS, 1992, 3 (04) :465-468

[6]

Biemond BJ, 2001, BLOOD, V98, p255A

[7] Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties [J].

Boffa, MB ;

Wang, W ;

Bajzar, L ;

Nesheim, ME .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :2127-2135

[8] Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor [J].

Boffa, MB ;

Bell, R ;

Stevens, WK ;

Nesheim, ME .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (17) :12868-12878

[9] New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; Plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R) [J].

Bouma, BN ;

Meijers, JCM .

SEMINARS IN HEMATOLOGY, 2004, 41 (01) :13-19

[10] Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) [J].

Bouma, BN ;

Marx, PF ;

Mosnier, LO ;

Meijers, JCM .

THROMBOSIS RESEARCH, 2001, 101 (05) :329-354

← 1 2 3 4 5 6 →